PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category
- New category targets programs that support the transition from adolescence to adulthood -
- Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 -
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., Jan. 14, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh annual STRIVE Awards program for Duchenne muscular dystrophy. The Awards provide a grant to patient advocacy organizations around the world who are committed to developing innovative and sustaining programs that help address the unmet needs of the rare disease community. This year, a new entry category dedicated to supporting programs that focus on the transition of those living with Duchenne from adolescence to adulthood has been introduced.